Antibe Therapeutics Aktie - ATE

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,405

Gebot

0,405

Fragen

0,41

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

0,405

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual...

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Inc.: - Phase II secondary data confirmed remarkable potency of ATB-346 - - 3rd party commercial studies project peak...

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain - - ATB-346 is more potent than expected; lowest effective...

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain...

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th...

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and...

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week...

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter...

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4th International Conference on the Biology of...

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ATE - Frequently Asked Questions (FAQ)

What is the current Antibe Therapeutics share price?

The current share price of Antibe Therapeutics is $ 0,405

What is the 1 year trading range for Antibe Therapeutics share price?

Antibe Therapeutics has traded in the range of $ 0,00 to $ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
FINV.PFaction Investment Group Corp	$ 0,15 (200,00%)	11k
WAV.HPepcap Resources Inc	$ 0,03 (200,00%)	15,44k
MTBMTB Metals Corp	$ 0,02 (100,00%)	317k
ETUE2gold Inc	$ 0,01 (100,00%)	235,35k
SOP.HSoperior Fertilizer Corp	$ 0,01 (100,00%)	12,01k
CANDCandelaria Mining Corp	$ 0,005 (-50,00%)	4,24k
SSESilver Spruce Resources Inc	$ 0,005 (-50,00%)	1,5k
CLMConsolidated Lithium Metals Inc	$ 0,005 (-50,00%)	169,55k
TOTC.PTotec Resources Ltd	$ 0,12 (-46,67%)	30k
MDMMadoro Metals Corp	$ 0,025 (-44,44%)	229k
SIGSitka Gold Corp	$ 0,52 (1,96%)	4,1M
NFGNew Found Gold Corp	$ 1,69 (3,05%)	2,26M
RPXRed Pine Exploration Inc	$ 0,115 (0,00%)	2,09M
FORFortune Bay Corp	$ 0,41 (13,89%)	2,05M
CDPRCerro de Pasco Resources Inc	$ 0,31 (1,64%)	2,03M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Antibe Therapeutics Inc (ATE)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ATE Neueste Nachrichten

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

ATE - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Antibe Therapeutics Inc (ATE) Börsenkurse

Antibe Therapeutics Inc (ATE)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ATE Neueste Nachrichten

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

ATE - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS